Payment overview · 2025
General Payments
$431.30
23 reported records · 12 companies
Healthcare provider profile · identity verified
John Charles Mcduff, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FAIRHOPE, AL · NPI 1467410530
Verified facts
What the public records show
CMS Open Payments records show John Charles Mcduff, M.D. received $431.30 in general payments during 2025 across 23 reported records.
Novartis Pharmaceuticals Corporation accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $65.30 | 15.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.42 | 13.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.90 | 12.5% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $38.88 | 9.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.88 | 8.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.44 | 8.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.99 | 8.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.77 | 8.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.64 | 5.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.39 | 5.0% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $17.37 | 4.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.32 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $431.30 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $65.30 | 3 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $38.88 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $38.88 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $38.88 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.52 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.52 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $36.88 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.44 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.71 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE TRIVALENT Normalized: fluzone trivalent |
Biological | SANOFI PASTEUR INC. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 361 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 341 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 300 | 90 |
| Omeprazole | Omeprazole | 229 | 64 |
| Alprazolam | Alprazolam | 186 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 56 |
| Losartan Potassium | Losartan Potassium | 174 | 53 |
| Tramadol Hcl | Tramadol Hcl | 162 | 30 |
| Allopurinol | Allopurinol | 155 | 43 |
| Gabapentin | Gabapentin | 144 | 41 |
| Potassium Chloride | Potassium Chloride | 138 | 44 |
| Simvastatin | Simvastatin | 138 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 39 |
| Metformin Hcl Er | Metformin Hcl | 122 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 34 |
| Lisinopril | Lisinopril | 105 | 28 |
| Furosemide | Furosemide | 101 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 28 |
| Trazodone Hcl | Trazodone Hcl | 98 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 17 |
| Meloxicam | Meloxicam | 84 | 25 |
| Metformin Hcl | Metformin Hcl | 83 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 24 |
| Famotidine | Famotidine | 77 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 23 |
| Celecoxib | Celecoxib | 70 | 24 |
| Sertraline Hcl | Sertraline Hcl | 69 | 24 |
| Clonazepam | Clonazepam | 68 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 20 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 61 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 22 |
| Atenolol | Atenolol | 59 | 15 |
| Glimepiride | Glimepiride | 58 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 57 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 54 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 11 |
| Azithromycin | Azithromycin | 47 | 39 |
| Carvedilol | Carvedilol | 45 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Eliquis | Apixaban | 42 | 11 |
| Methylprednisolone | Methylprednisolone | 39 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | 12 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Diazepam | Diazepam | 35 | 11 |
| Estradiol | Estradiol | 34 | 11 |
| Temazepam | Temazepam | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 11 |
| Lorazepam | Lorazepam | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | 12 |
| Cephalexin | Cephalexin | 31 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Ozempic | Semaglutide | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 17 |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 25 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 20 |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Prednisone | Prednisone | 20 | 12 |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $431.30 · 23 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, AREXVY, Azstarys, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE TRIVALENT, LEQVIO, MOUNJARO, Ozempic, QULIPTA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, WaveWriter Alpha Prime 16, Wegovy, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error